Ambalal Sarabhai Enterprises
Healthcare
AMBALALSA NSE
₹36.14 +1.31 (+3.76%)
- P/E
- 66.93
Close 4 Nov 2026 ₹36.14 +4.24 +13.3% 1Y
Start ₹31.90
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 16.40%
- Debt to Equity
- 0.18
- EPS (TTM)
- ₹0.54
- Book Value
- ₹20.66
- Market Cap
- —
- P/E (TTM)
- 66.93
- P/B
- 1.75
- ROE
- 20.40%
- Dividend Yield
- 0.00%
- EBITDA
- ₹26.90 Cr
- 52W High
- ₹49.98
- 52W Low
- ₹23.12
- Day Range
- ₹34.60 – ₹36.54
- Volume
- 18,394
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Ambalal Sarabhai Enterprises (this company) | ₹36.14 | 66.93 | ₹265 Cr | 1.75 | 0.00% | 20.40% | 16.40% | ₹3 Cr | ₹4 Cr |
| Median 8 companies | ₹1,587.70 | 52.87 | ₹1,25,337 Cr | 4.57 | 0.44% | 17.40% | 17.10% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
43 Weak
Data confidence 100/100
surveillance:ESM1
Category scores
- Quality
- 49
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 39
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 6
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 64
- Good
- Solvency, leverage, coverage 9% weight
- Momentum
- 71
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
6- Stock is trading at 4.46 times its book value
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 12.1% over last 3 years.
- Earnings include an other income of Rs.9.11 Cr.
- Working capital days have increased from 267 days to 1,379 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 9 | 6 | 4 |
| Oscillators | Bearish | 3 | 6 | 0 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Bearish
Bearish
3
Neutral
6
Bullish
0
Overall
Bearish
Bearish
9
Neutral
6
Bullish
4
Moving Averages
Strong Bearish
Bearish
6
Neutral
0
Bullish
4
Key readings
- RSI (14)
- 44.42
- Neutral
- MACD (12,26,9)
- −1.25
- Bearish
- SMA (50)
- 39.65
- Bearish
- SMA (200)
- 33.38
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −5.56% |
|---|---|
| 5Y | Zero base |
| 3Y | +2.03% |
| 1Y | −2.48% |
| TTM | −37.22% |
Net profit
| 10Y | −13.28% |
|---|---|
| 5Y | Turned to profit |
| 3Y | +38.80% |
| 1Y | +33.37% |
| TTM | −71.76% |
Operating cash flow
| 10Y | Outflow narrowed by ₹69.11 Cr |
|---|---|
| 5Y | Outflow narrowed by ₹10.16 Cr |
| 3Y | Turned negative |
| 1Y | Outflow narrowed by ₹3.82 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +180.08 pp |
|---|---|
| 5Y | No sales |
| 3Y | +9.13 pp |
| 1Y | +51.49 pp |
| TTM | −21.14 pp |
Revenue by year
| Mar 2017 | ₹1.51 Cr |
|---|---|
| Mar 2018 | ₹0.92 Cr |
| Mar 2019 | ₹0.00 Cr |
| Mar 2020 | ₹0.00 Cr |
| Mar 2021 | ₹0.00 Cr |
| Mar 2022 | ₹0.13 Cr |
| Mar 2023 | ₹3.71 Cr |
| Mar 2024 | ₹3.81 Cr |
| Mar 2025 | ₹4.04 Cr |
| Mar 2026 | ₹3.94 Cr |
Net profit by year
| Mar 2017 | −₹20.57 Cr |
|---|---|
| Mar 2018 | −₹1.44 Cr |
| Mar 2019 | −₹3.88 Cr |
| Mar 2020 | ₹15.55 Cr |
| Mar 2021 | −₹9.39 Cr |
| Mar 2022 | ₹2.96 Cr |
| Mar 2023 | ₹4.11 Cr |
| Mar 2024 | ₹2.58 Cr |
| Mar 2025 | ₹8.24 Cr |
| Mar 2026 | ₹10.99 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.7 | 0.8 | 0.33 | 0.99 | 1.14 | 0 | 1.17 | 1.73 | 1.64 | 0.79 | 0 | 1.52 | 0.54 |
| Expenses | 4.84 | 2.13 | 1.96 | 1.64 | 2.41 | 1.8 | 3.74 | 3.43 | 2.83 | 2.43 | 0.94 | 2.88 | 1.76 |
| Operating Profit | −3.14 | −1.33 | −1.63 | −0.65 | −1.27 | −1.8 | −2.57 | −1.7 | −1.19 | −1.64 | −0.94 | −1.36 | −1.22 |
| OPM % | −184.71% | −166.25% | −493.94% | −65.66% | −111.4% | — | −219.66% | −98.27% | −72.56% | −207.59% | — | −89.47% | −225.93% |
| Other Income | 1.18 | 1.96 | 1.33 | 3.41 | 1.88 | 6.37 | 10.81 | −3.21 | 8.17 | 1.36 | 2.89 | 3.16 | 1.7 |
| Interest | 0.03 | 0.04 | 0.06 | 0.07 | 0.09 | 0.09 | 0.1 | 0.05 | 0.07 | 0.08 | 0.09 | 0.17 | 0.17 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| PBT | −2.02 | 0.56 | −0.39 | 2.66 | 0.49 | 4.45 | 8.12 | −4.98 | 6.89 | −0.38 | 1.84 | 1.61 | 0.29 |
| Tax % | 0% | 0% | 69.23% | −76.32% | 6.12% | 3.15% | −3.82% | −0.4% | 0% | 0% | −0.54% | −64.6% | 89.66% |
| Net Profit | −2.02 | 0.56 | −0.65 | 4.7 | 0.46 | 4.31 | 8.43 | −4.96 | 6.88 | −0.38 | 1.84 | 2.65 | 0.03 |
| EPS (₹) | −0.26 | 0.07 | −0.08 | 0.61 | 0.06 | 0.56 | 1.1 | −0.65 | 0.9 | −0.05 | 0.24 | 0.35 | 0 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.25 | 6.98 | 1.51 | 0.92 | 0 | 0 | 0 | 0.13 | 3.71 | 3.81 | 4.04 | 3.94 | 2.85 |
| Expenses | 27.3 | 28.62 | 14.47 | 21.76 | 8.86 | 7.86 | 11.69 | 5.71 | 8.87 | 8.61 | 11.37 | 9.06 | 8.01 |
| Operating Profit | −12.05 | −21.64 | −12.96 | −20.84 | −8.86 | −7.86 | −11.69 | −5.58 | −5.16 | −4.8 | −7.33 | −5.12 | −5.16 |
| OPM % | −79.02% | −310.03% | −858.28% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — | — | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −139.08% | −125.98% | −181.44% | −129.95% | −181.05% |
| Other Income | 14.17 | 95.94 | −0.63 | 24.49 | 6.46 | 24.61 | 3.16 | 9.47 | 9.75 | 7.89 | 15.85 | 15.57 | 9.11 |
| Interest | 7.91 | 1.99 | 2.62 | 1.05 | 0.62 | 0.46 | 0.56 | 0.25 | 0.11 | 2.16 | 0.34 | 0.41 | 0.51 |
| Depreciation | 3.36 | 14.62 | 2.45 | 0.42 | 0.4 | 0.39 | 0.38 | 0.19 | 0.15 | 0.12 | 0.1 | 0.09 | 0.08 |
| PBT | −9.15 | 57.69 | −18.66 | 2.18 | −3.42 | 15.9 | −9.47 | 3.45 | 4.33 | 0.81 | 8.08 | 9.95 | 3.36 |
| Tax % | 0% | 20.8% | 10.18% | 166.06% | 13.45% | 2.2% | −0.84% | 14.49% | 5.31% | −217.28% | −1.98% | −10.45% | — |
| Net Profit | −9.15 | 45.68 | −20.57 | −1.44 | −3.88 | 15.55 | −9.39 | 2.96 | 4.11 | 2.58 | 8.24 | 10.99 | 4.14 |
| EPS (₹) | −1.19 | 5.96 | −2.68 | −0.19 | −0.51 | 2.03 | −1.23 | 0.39 | 0.54 | 0.34 | 1.08 | 1.43 | 0.54 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 |
| Reserves | −73.49 | −27.8 | −46.41 | −47.98 | −51.85 | −36.39 | −45.85 | −42.93 | −38.79 | −36.34 | −28.14 | −17.15 |
| Borrowings | 30.1 | 29.54 | 22.13 | 11.07 | 11.07 | 11 | 11.14 | 9.77 | 11.49 | 10.03 | 7.66 | 11 |
| Other Liabilities | 103 | 65.13 | 63.81 | 91.28 | 103 | 73.35 | 58.14 | 39.53 | 30.42 | 30.96 | 26.77 | 15.31 |
| Total Liabilities | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 79.75 | 81.28 | 82.92 | 85.79 |
| Fixed Assets | 42.66 | 20.6 | 16.43 | 14.98 | 14.65 | 14.48 | 13.97 | 13 | 12.86 | 12.84 | 12.22 | 12.13 |
| CWIP | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 56.29 | 82.91 | 76.19 | 55.88 | 55.97 | 56.43 | 26.58 | 25.54 | 25.54 | 25.39 | 25.34 | 25.34 |
| Other Assets | 37.43 | 39.99 | 23.54 | 60.14 | 68.01 | 53.68 | 59.51 | 44.46 | 41.35 | 43.05 | 45.36 | 48.32 |
| Total Assets | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 79.75 | 81.28 | 82.92 | 85.79 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −12.05 | −69.37 | −3.67 | −12.66 | −3.27 | −4.53 | −10.42 | −7.79 | 1.52 | −3.82 | −4.08 | −0.26 |
| Investing | 12.7 | 75.22 | 8.64 | 26.14 | 2.37 | 4.92 | 15.76 | 20.77 | 0.61 | 3.48 | 6.35 | −3.02 |
| Financing | −0.75 | −2.56 | −8.14 | −12.15 | −0.44 | −0.42 | −0.32 | −16.46 | −3.76 | 0.3 | −2.31 | 3.4 |
| Net Cash Flow | −0.1 | 3.3 | −3.17 | 1.33 | −1.33 | −0.03 | 5.02 | −3.47 | −1.63 | −0.04 | −0.04 | 0.11 |
| Free Cash Flow | −0.49 | 31.11 | −3.04 | 1.72 | −3.33 | −4.5 | 0.66 | 11.47 | 1.58 | −3.91 | 1.11 | −0.27 |
| CFO/EBITDA | 71 | 304 | 27 | −24 | −11 | 51 | 85 | 128 | −45 | 65 | 47 | 61 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 37.34 | 1.57 | 0 | 0 | — | — | — | 421 | 29.51 | 37.36 | 37.04 | 38.91 |
| Inventory Days | 76.36 | 22.52 | 47.93 | 56.64 | — | — | — | 0 | 2.01 | 0 | 0 | 6.62 |
| Days Payable | 321 | 729 | 3,974 | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — | — | — | — | 1,612 | — | — | 712 |
| Cash Conversion Cycle | −207 | −705 | −3,927 | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — | — | — | 421 | −1,580 | 37.36 | 37.04 | −667 |
| Working Capital Days | −2,355 | −3,036 | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — | — | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −1,038 | −687 | 109 | 1,379 |
| ROCE % | −34.09% | −59.62% | −12.82% | −21.98% | −7.41% | 36.9% | −4.27% | 9.93% | 11.12% | 5.96% | 6.01% | 16.36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ambalal Sarabhai Enterprises insights
30 extracted metrics across FY15–FY27.
Documents
- Q3 FY26 concall · Feb 2026Transcript PPT
- Concall · Dec 2025Transcript PPT
- 21 May 2026
- 1 Mar 2016
- 19 Jan 2016
- General announcements 6 Oct 2026
Frequently Asked Questions about Ambalal Sarabhai Enterprises
What does Ambalal Sarabhai Enterprises Ltd do?
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics
Where is Ambalal Sarabhai Enterprises Ltd (AMBALALSA) listed?
Ambalal Sarabhai Enterprises Ltd trades as AMBALALSA on the NSE and under code 500009 on the BSE.
Which sector does Ambalal Sarabhai Enterprises Ltd belong to?
Ambalal Sarabhai Enterprises Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd trades at a PE ratio of 66.93 as of 4 Nov 2026, on earnings per share of ₹0.54, against a book value of ₹20.66 per share.
What is the 52-week high and low of Ambalal Sarabhai Enterprises Ltd?
Over the last 52 weeks Ambalal Sarabhai Enterprises Ltd has traded between ₹23.12 and ₹49.98 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd reported a return on equity of 20.40%. Its debt-to-equity ratio is 0.18.
Company Information
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/500009.md for Ambalal Sarabhai Enterprises Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.